China: Chinese Investors Investing In One Belt One Road Lack An Effective Enforcement Mechanism At Home

Last Updated: 2 December 2019
Article by Anton A. Ware

Encouraged by the Chinese Government's expansive Belt and Road Initiative, and often relying on the investor protections afforded to them under China's dense network of investment treaties, Chinese companies are investing overseas in record numbers. As the volume of such outbound investment has grown, so too has the number of disputes between Chinese investors and host States regarding alleged violations of investment treaty protections. Unless settled amicably, those disputes generally are subject to resolution through investment treaty arbitration, most often under (1) the Convention on the Settlement of Investment Disputes between States and Nationals of other States ("ICSID Convention") and the ICSID Arbitration Rules, or (2) in the case of ad hoc arbitration, the United Nations Commission on International Trade Law Rules ("UNCITRAL Rules"). In bringing such cases, investors are relying on the ability—if necessary—to enforce a favorable arbitration award against the host State under the ICSID Convention or the United Nations Convention on the Recognition and Enforcement of Foreign Arbitral Awards (1958) ("New York Convention"), respectively. Given that China is a party to both Conventions, a Chinese investor could be forgiven for assuming that it would be able to obtain recognition and enforcement of a favorable investment treaty arbitration award in its own "home" courts (Chinese courts), and to obtain the assistance of such courts in executing the award against any commercial assets of the host State in China. But such an assumption would appear to be wrong. This article highlights the various obstacles that China's adherence to the doctrine of absolute sovereign immunity pose to enforcement of investment treaty arbitration awards in China.

China's Adherence to Absolute Sovereign Immunity

"Sovereign immunity"—known in some jurisdictions as "State immunity"—refers to the customary international law principle that sovereign States enjoy immunity from suit in the courts of another State ("immunity from suit") as well as immunity from execution of a judgment against State assets by the authorities of another State ("immunity from execution"), unless such immunity has been waived. In recent decades, an increasing number of States have abandoned the purest form of the sovereign immunity doctrine—"absolute" sovereign immunity—and adopted in its place a more limited form of the doctrine known as "restrictive" sovereign immunity. Under a restrictive sovereign immunity regime, a foreign State's immunity is limited to claims relating to the State's sovereign conduct, and does not extend to suits arising from the State's commercial activities or to execution against commercial assets of the State.

China has thus far resisted the trend toward a narrower scope of immunity, continuing instead to adhere to the absolute sovereign immunity doctrine. The PRC Government reiterated this stance in 2008 and 2009 in formal communications to the Hong Kong government in connection with the case of FG Hemisphere Associates LLC v Democratic Republic of Congo (2011) 14 HKCFAR 95. In that case, the Hong Kong Court of Final Appeal accepted the PRC government's submission that as a matter of PRC law and policy, State immunity covers not only a State's sovereign acts but also its commercial activities. Simply put, the PRC Government's position, as expressed in the FG Hemisphere case and thereafter, is that China follows the doctrine of absolute sovereign immunity and its courts do not adjudicate cases in which a foreign sovereign is named as the defendant (full stop).

Implications for recognition and enforcement of investor-State arbitration awards in China

Although the precise mechanism differs from jurisdiction to jurisdiction, the typical procedure for seeking recognition and enforcement of an arbitration award is for the award creditor (the winning party in the arbitration) to file a lawsuit in an appropriate court in the jurisdiction of intended enforcement, naming the award debtor (the losing party in the arbitration) as the defendant, and asking the court to convert the award into a judgment. After the award is converted into a judgment, the award creditor may then execute that judgment against the assets of the award debtor, using whatever procedures are available for that purpose in the enforcement jurisdiction. In the case of an investor-State arbitration, the first step in this procedure requires a successful claimant to commence a lawsuit in the enforcement jurisdiction naming the respondent State as the defendant. In an absolute sovereign immunity jurisdiction, however, the filing of such a lawsuit against the respondent State is not permitted, thus frustrating the claimant's ability to recognize or enforce the award.

Such appears to be the case in China. Although there is no statutory provision or judicial interpretation directly addressing the issue, the logic of the Chinese Government's position in the FG Hemisphere case suggests that a Chinese court would reject on sovereign immunity grounds an action to recognize or enforce an arbitration award against a sovereign State or any assets of a sovereign State. The FG Hemisphere case itself involved an attempt by a successful claimant to enforce two ICC arbitration awards against the Democratic Republic of Congo (among other respondents) in the Hong Kong courts. In response to a request by the Hong Kong Court of Final Appeal in that case, the Standing Committee of the National People's Congress of the PRC clarified that Chinese courts do not exercise, and have never exercised, jurisdiction over cases in which a foreign State is named as the defendant. It is thus not surprising that there does not appear to be even a single reported case in a Mainland Chinese court involving recognition or enforcement of an arbitration award against a foreign State (or any agency or instrumentality of a foreign State).

Relevance of the New York Convention and the ICSID Convention

A question arises as to whether China's stance on absolute sovereign immunity is consistent with its obligations as a Party to the New York Convention and the ICSID Convention, which create obligations on the part of member States to recognize and enforce arbitration awards within their respective ambits. Specifically, the New York Convention obligates member States (including China) to recognize and enforce international arbitration awards issued in another member State ("New York Convention awards"), subject only to certain narrow, enumerated exceptions. Other than ICSID awards (discussed below), investor-State arbitration awards—including ad hoc awards under the UNCITRAL Rules—generally will fall within the broad scope of coverage of the New York Convention. The ICSID Convention, for its part, creates a mandatory and exclusive regime for recognition and enforcement of ICSID awards by ICSID Convention member States (including China).

New York Convention. The New York Convention does not contain any provision expressly addressing the question of sovereign immunity. Article V(2)(b) of the Convention, however, permits a member State to refuse recognition and enforcement of a New York Convention award on public policy grounds. The sovereign immunity doctrine is a quintessential subject of public policy—especially in jurisdictions such as China that adhere to an absolute sovereign immunity regime. The New York Convention thus does not override any member State's law of sovereign immunity.

ICSID Convention. Unlike the New York Convention, the ICSID Convention expressly addresses the issue of sovereign immunity. Under Article 54(1) of the ICSID Convention, each member State is obligated to (1) "recognize an award rendered pursuant to [the ICSID] Convention as binding," and (2) "enforce the pecuniary obligations imposed by that award within its territories as if it were a final judgment of a court in that State." Article 54(3) stipulates that execution of an ICSID award shall be governed by the laws concerning execution of judgments in force in the State of enforcement. Article 55 then provides an important clarification regarding sovereign immunity: "Nothing in Article 54 shall be construed as derogating from the law in force in any Contracting State relating to immunity of that State or of any foreign State from execution" (emphasis added). Read together, Articles 54 and 55 make clear: (i) the ICSID Convention does not override any member State's domestic law with respect to sovereign immunity from execution; (ii) by ratifying the ICSID Convention, a State does not waive its own sovereign immunity from execution; however, (iii) the ICSID Convention does not permit domestic law immunity from suit to act as a bar to proceedings for the recognition of an ICSID award. China thus arguably has an international law obligation under the ICSID Convention to grant recognition to an ICSID award brought before a Chinese court for such purpose (i.e., to convert such an award to a judgment), notwithstanding any sovereign immunity doctrine to the contrary.

From the perspective of a claimant that has obtained a favorable ICSID award and wishes to enforce it in China, however, numerous legal and practical obstacles remain. First, China has not enacted legislation or promulgated any judicial guidance regarding implementation of the ICSID Convention, and as a result, it remains unclear whether a Chinese court would be able or willing to apply the Convention to a case brought before it. Second, it is not clear whether a Chinese court would accept the proposition discussed above, namely that the ICSID Convention effectively overrides each member State's doctrine of sovereign immunity insofar as recognition of ICSID awards is concerned. Third, even if the first two obstacles could be overcome, the most that the award creditor could achieve would be to convert its ICSID award to a Chinese court judgment—something of a pyrrhic victory given that the award debtor would remain absolutely immune from execution of that judgment in China.

The question of waiver

The general rule in restrictive sovereign immunity jurisdictions (often codified in national legislation) is that by agreeing to arbitrate a given category of disputes (e.g., in an investment contract or investment treaty), a State has implicitly waived its right to assert sovereign immunity as a defense to actions (1) to enforce that arbitration agreement, and (2) to recognize a final arbitration award arising from that agreement (sovereign immunity typically remains available in such jurisdictions as a defense to execution against sovereign (non-commercial) assets). In absolute sovereign immunity jurisdictions, by contrast, implicit waiver of sovereign immunity is either not recognized at all or is given a far more narrow scope.

Can Chinese investors entering into investment agreements with foreign States overcome the obstacles described in this article by insisting that the State agree to an express waiver of sovereign immunity? Not necessarily. The Hong Kong Court of Final Appeal held in the FG Hemisphere case that under common law principles, a pre-dispute waiver of immunity is insufficient to effect a waiver—only an express waiver of immunity from both suit and execution before the Hong Kong courts would suffice. The authors are not aware of any Mainland Chinese statutory provision, court decision, or Supreme People's Court interpretation addressing the effectiveness of a pre-dispute waiver of sovereign immunity. Chinese investors, therefore, are in uncharted territory when it comes to determining the requirements for a valid waiver. That said, from the investor's perspective, there would seem to be no harm in including such a waiver provision in the investment contract, if the host State is willing to accept such a provision.

Future directions

As unlikely as it may seem, at present Chinese investors face a significant home court "disadvantage" in attempting to enforce a favorable arbitration award against a foreign State's assets in China in a Chinese court. There are some signs that China may be considering an eventual shift toward restrictive sovereign immunity. In 2005, China signed the United Nations Convention on Jurisdictional Immunities of States and Their Property, which implements a restrictive immunity approach. But China has not yet ratified this Convention, and has not yet accepted the policy framework that it reflects. Unless and until China embraces the restrictive immunity approach, Chinese investors that prevail in investment treaty arbitration will be left to rely on voluntary compliance by the host State or enforcement in other jurisdictions in which the host State has commercial assets and in which the courts apply a restrictive form of sovereign immunity.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions